Syros Pharmaceuticals, Inc. (SYRS)
OTCMKTS
· Delayed Price · Currency is USD
0.0253
-0.0047 (-15.67%)
Mar 31, 2025, 3:01 PM EST
Syros Pharmaceuticals Revenue
Syros Pharmaceuticals had revenue of $386.00K in the twelve months ending September 30, 2024, down -95.61% year-over-year. In the year 2023, Syros Pharmaceuticals had annual revenue of $9.94M, down -33.23%.
Revenue (ttm)
386.00K
Revenue Growth
-95.61%
P/S Ratio
2.86
Revenue / Employee
5.68K
Employees
68
Market Cap
804.97K
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.94M | -4.94M | -33.23% |
Dec 31, 2022 | 14.88M | -8.61M | -36.65% |
Dec 31, 2021 | 23.49M | 8.40M | 55.62% |
Dec 31, 2020 | 15.09M | 13.11M | 661.50% |
Dec 31, 2019 | 1.98M | -68.00K | -3.32% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
SS Innovations International | 16.04M |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 200.90M |
Northwest Biotherapeutics | 1.60M |
Silence Therapeutics | 43.26M |
American Oncology Network | 1.76B |
Syros Pharmaceuticals News
- 4 weeks ago - Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration - Business Wire
- 4 months ago - Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default - Benzinga
- 4 months ago - Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression - Business Wire
- 5 months ago - The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions - Accesswire
- 5 months ago - Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm - Accesswire
- 5 months ago - The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations - Accesswire
- 5 months ago - Syros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm - Accesswire